BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 10, Issue 9
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study
©The Author(s) 2018.
World J Hepatol. Sep 27, 2018; 10(9): 612-621
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.612
Table 4 Mean difference in hemoglobin A1c by hepatitis C virus genotype and direct acting antiviral treatment
Average change HbA1c (SE)P-value
HCV genotype
1a-0.73 (0.13)0.97
1b-0.69 (0.20)
2-0.79 (0.27)
3-0.88 (0.51)
4-0.20 (NA)
Treatment
Sofosbuvir/Simeprevir-0.71 (0.16)0.97
Sofosbuvir/Ribavirin-0.77 (0.27)
PrOD-0.66 (0.15)
Ledipasvir/Sofosbuvir-0.80 (0.24)
HbA1c: Hemoglobin A1c; HCV: Hepatitis C virus; PrOD: Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.